GLP-1 & compounded medication availability in Missouri (2026)
Missouri keeps its compounding oversight general-purpose, and nothing from the state’s pharmacy regulators singles out GLP-1s or research peptides. What Missouri does insist on is the permit trail: an out-of-state pharmacy needs the state’s own nonresident permit before a package crosses the state line, and that one credential is the thing worth verifying on any telehealth order shipped to a Missouri address.
What ships to Missouri: all ten lines
| Product line | Available in Missouri? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Fulfilled by partner pharmacies holding the Missouri nonresident permit. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | One national price at every dose, so Missouri pays the same. |
| NAD+ | Yes | 8–10 business days | Same ordering flow as the weight-management lines. |
| Sermorelin | Yes | 8–10 business days | Ships without any Missouri-specific condition. |
| Glutathione | No | N/A | Not something OrderlyMeds offers today. |
| BPC-157 | Yes | 8–10 business days | Injectable line; federal record below. |
| TB-500 | Yes | 8–10 business days | Compounded injectable. Details in its federal section. |
| KPV | No | N/A | Injectable-only formulary; this line is not in it. |
| Epitalon | Yes | 8–10 business days | Injectable; the federal picture sits below. |
| MOTS-c | Yes | 8–10 business days | Injectable with a federal record distinct from its siblings, below. |
Where the answer is No the table says No. Missouri rows were last checked on November 16, 2026.
Research peptides in Missouri: BPC-157, TB-500, KPV, Epitalon & MOTS-c
Four of the five research-peptide lines ship to Missouri addresses, BPC-157, TB-500, Epitalon and MOTS-c, each as a compounded injectable filled on a patient-specific prescription. KPV does not ship anywhere: we compound these lines as injectables only. What follows is each line’s federal record, stated per substance because the five records are not interchangeable.
BPC-157 in Missouri
Part of the Missouri offering as a compounded injectable, on a patient-specific prescription. Read both federal facts below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Missouri
Ships to Missouri as a compounded injectable under a patient-specific prescription; its federal record follows.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Missouri
Not available in Missouri or anywhere else, because the OrderlyMeds peptide formulary is injectable-only and KPV sits outside it.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Missouri
A Missouri-eligible compounded injectable on a patient-specific prescription. Geography changes nothing in the record below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Missouri
Ships to Missouri as a compounded injectable, patient-specific prescription required. Its record below is deliberately not the wording the other four carry.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Missouri’s pharmacy regulators say about compounded medications
Missouri’s posture is baseline: general compounding and licensure rules, applied evenly, with no medication-category carve-outs. For a Missouri patient the load-bearing fact is the nonresident permit. It is what connects an out-of-state telehealth pharmacy to the state’s own oversight.
A nonresident pharmacy must obtain a Missouri nonresident pharmacy permit from the Missouri Board of Pharmacy before shipping, mailing, or dispensing prescription medications to Missouri patients (20 CSR 2220-2.025). Source: Missouri Board of Pharmacy — 2026 Pharmacy Practice Guide.
The Missouri Board of Pharmacy regulates compounding under its general statutes and rules and has published no rule, order, or guidance specific to GLP-1 medications or peptide compounding. Source: Missouri Board of Pharmacy — Statutes & Rules.
Missouri permits prescriptions issued on the basis of a telemedicine encounter meeting the standard of care; no in-person-first requirement applies to the medication lines on this page. Source: Center for Connected Health Policy (CCHP) Policy Finder.
A Missouri order follows the standard path: eligibility check online, evaluation by a Missouri-licensed provider, fulfillment by a licensed partner pharmacy holding the permit above. The price is national; Kansas City and St. Louis pay what every other city pays.
Missouri availability FAQs
Does compounded semaglutide ship to Missouri?
Yes. Licensed partner pharmacies with the Missouri nonresident permit fill and ship it, starting at $74/month for the first two months.
What credential should a pharmacy shipping to Missouri hold?
A Missouri nonresident pharmacy permit. The cited regulator section above carries the rule number and source.
Which research peptides can Missouri patients order?
BPC-157, TB-500, Epitalon and MOTS-c as compounded injectables on a patient-specific prescription; KPV is not in our formulary. Each line’s own federal record is stated above.
Is there a Missouri price difference?
No. Pricing is national, so the posted price is the Missouri price at every dose.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
